Secretome Therapeutics: Pioneering nCPC-Based Cardiovascular Therapies
  • Home
  • Pipeline
  • Leadership
  • News & Publications
    • News
    • Publications
Select Page

Comparative efficacy and mechanism of action of cardiac progenitor cells after cardiac injury

by Sudhish Sharma | Jun 17, 2022 | Journals, Uncategorized

Abstract Gunasekaran et al demonstrate that human neonatal Mesenchymal Stem Cells (nMSCs) evade from macrophage mediated phagocytosis via increased CD47 expression and to promote functional recovery by secretion of exosomes and independent cytokines. The increased...

Circulating exosomes derived from transplanted progenitor cells aid the functional recovery of ischemic myocardium

by Sudhish Sharma | May 22, 2019 | Journals, Uncategorized

Abstract The stem cell field is hindered by its inability to noninvasively monitor transplanted cells within the target organ in a repeatable, time-sensitive, and condition-specific manner. We hypothesized that quantifying and characterizing transplanted cell–derived...

Stem Cell Therapy for Hypoplastic Left Heart Syndrome: Mechanism, Clinical Application, and Future Directions

by Sudhish Sharma | Jul 6, 2018 | Journals, Uncategorized

Abstract Hypoplastic left heart syndrome is a type of congenital heart disease characterized by underdevelopment of the left ventricle, outflow tract, and aorta. The condition is fatal if aggressive palliative operations are not undertaken, but even after the complete...

Regenerative medicine therapy for single ventricle congenital heart disease

by Sudhish Sharma | Apr 2, 2018 | Journals, Uncategorized

Abstract One of the most complex forms of congenital heart disease (CHD) involving single ventricle physiology is hypoplastic left heart syndrome (HLHS), characterized by underdevelopment of the left ventricle (LV), mitral and aortic valves, and narrowing of the...

The current status and future of cardiac stem/progenitor cell therapy for congenital heart defects from diabetic pregnancy

by Sudhish Sharma | Jan 10, 2018 | Journals, Uncategorized

Abstract Pregestational maternal diabetes induces congenital heart defects (CHDs). Cardiac dysfunction after palliative surgical procedures contributes to the high mortality of CHD patients. Autologous or allogeneic stem cell therapies are effective for improving...
« Older Entries

Recent Posts

  • Secretome Therapeutics Appoints Dr. Marshelle Smith Warren as Chief Medical Officer
  • Secretome Therapeutics Announces First Patient Dosed in Groundbreaking Phase 1 Study of STM-01 in Heart Failure with Preserved Ejection Fraction
  • Secretome Therapeutics Granted FDA Fast Track Designation for STM-01, a Neonatal Cardiac Progenitor Cell Therapy for HFpEF
  • Cellipont Bioservices and Secretome Therapeutics Partner for cGMP Manufacturing for Master Cell Bank for Lead Asset STM-01
  • Secretome Therapeutics Closes $20.4 Million Financing Round to Advance Cardiomyopathy and Heart Failure Therapies
© 2025 Secretome Therapeutics | Brady UX